

# Mattia Zampieri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2940869/publications.pdf>

Version: 2024-02-01

20  
papers

241  
citations

932766

10  
h-index

1058022

14  
g-index

20  
all docs

20  
docs citations

20  
times ranked

168  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis. <i>International Journal of Cardiology</i> , 2022, 351, 71-77.	0.8	11
2	SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. <i>Internal and Emergency Medicine</i> , 2022, 17, 1243-1245.	1.0	7
3	Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. <i>Internal and Emergency Medicine</i> , 2022, 17, 957-969.	1.0	6
4	Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis. <i>Journal of Cardiac Failure</i> , 2022, 28, 950-959.	0.7	8
5	Incidence and risk factors for pacemaker implantation in light chain and transthyretin cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2022, 24, 1227-1236.	2.9	28
6	Cardiac magnetic resonance in patients with ARVC and family members: the potential role of native T1 mapping. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2037-2047.	0.7	5
7	Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 211-212.	1.4	9
8	Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 <i>Medicine</i> , 2021, 85, 68-79.	1.0	14
9	Emerging Medical Treatment for Hypertrophic Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 951.	1.0	18
10	Ventricular tachyarrhythmias and sudden cardiac death in light chain amyloidosis: a clash of cardio-toxicities?. <i>British Journal of Haematology</i> , 2021, 193, e27-e31.	1.2	5
11	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13598.	1.7	16
12	Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey. <i>ESC Heart Failure</i> , 2021, 8, 3369-3374.	1.4	18
13	Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. <i>Current Cardiology Reports</i> , 2021, 23, 79.	1.3	17
14	Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. <i>Current Heart Failure Reports</i> , 2021, 18, 169-179.	1.3	19
15	Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. <i>International Journal of Cardiology</i> , 2021, 335, 123-127.	0.8	21
16	Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2185-2191.	1.4	10
17	Prevalence and clinical correlates of exercise-induced ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. <i>International Journal of Cardiovascular Imaging</i> , 2021, , 1.	0.7	1
18	Prevalence and prognostic significance of RV uptake (biventricular uptake) at planar scintigraphy in patients with ATTR cardiac amyloidosis. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	1

#	ARTICLE	IF	CITATIONS
19	Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 318, 94-100.	0.8	15
20	Targeted Medical Therapies for Hypertrophic Cardiomyopathy. Current Cardiology Reports, 2020, 22, 10.	1.3	12